Indication
Treatment of adult patients with moderate to severe, active, autoantibody-positive systemic lupus erythematosus (SLE) who are receiving standard therapy.
Medicine details
- Medicine name:
- obinutuzumab (Gazyvaro)
- SMC ID:
- SMC3014
- Pharmaceutical company
- Roche
- BNF chapter
- Nutrition and blood
- Submission type
- Full
- Publication due date:
- TBC
- SMC meeting date:
- TBC
- Patient group submission deadline:
- TBC